| Document |
Document Title |
|
WO/2022/034544A1 |
This invention relates to a hydroxamate metalloprotease inhibitor compound for use in a method of diagnosing or treating cancer, inflammatory diseases or Alzheimer's disease. The compound comprises a zinc-chelating N-hydroxamate moiety r...
|
|
WO/2022/032353A1 |
Radiopharmaceutical compounds of general Formula (I) are based on a sarcophagine cage having a PEG linker-group X through to a group Y capable of binding to a biological receptor and an albumin-binding group Z for the treatment, diagnosi...
|
|
WO/2022/035222A1 |
The present invention relates to a peptide selectively binding to a cancer cell-derived exosome, and uses thereof. A peptide of ExoPep (CRKVAKG) has been discovered using a phage display technique to discover a peptide with specific bind...
|
|
WO/2022/034176A2 |
The invention relates to a delivery device formed by an aggregation of a plurality of individual particles in a host fluid, wherein one or more individual particles of the plurality of individual particles has a density of less than the ...
|
|
WO/2022/032844A1 |
A tumor stroma imaging agent. The tumor stroma imaging agent has the following chemical structural formula (I): wherein R is hydrogen or fluorine. Compared with the prior art, the tumor stroma imaging agent shows remarkable affinity for ...
|
|
WO/2022/028557A1 |
A 18F-labeled biphenyl compound, an intermediate thereof, a preparation method therefor, a pharmaceutical composition thereof, and application thereof. The biphenyl compound has a significant suppression effect on PD-1 and/or PD-L1, can ...
|
|
WO/2022/028745A1 |
The present invention relates to imaging probes, preferably radioactive compounds, (also referred to in the present invention as radiotracers) comprising a protein, preferably selected from the list consisting of collagen, fibronectin, a...
|
|
WO/2022/031925A1 |
Processes, systems, and apparatuses for producing 229Th, for producing 225Ac, for producing 213Bi, and for producing targeted radiologic treatments for cancer, are disclosed. Methods for treating and diagnosing cancer are also disclosed....
|
|
WO/2022/029294A1 |
The invention describes a method to differentiate tumour tissue from brown adipose tissue on a PET-CT scan. In particular, the invention concerns a method for discriminating primary tumour and/or metastases from brown and/or beige adipos...
|
|
WO/2022/023541A1 |
The present invention relates to a composition comprising (i) rapamycin and/or a rapalog and (ii) a radiolabeled gastrin analogue. The composition of the present invention can be used for the treatment and/or diagnosis of CCKB receptor p...
|
|
WO/2022/023554A1 |
The present invention relates to an alpha radiolabeled gastrin analogue and its use in peptide receptor radionuclide therapy (PRRT) applications. In particular, the present invention relates to an alpha radiolabeled gastrin analogue, whi...
|
|
WO/2022/026533A1 |
Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in ...
|
|
WO/2022/023677A1 |
The invention relates to a statistical polysaccharide with a weight-average molecular weight of between 100 kDa and 1000 kDa of the following formula (I): in which: each Rc independently represents a group containing a chelating agent, e...
|
|
WO/2022/025129A1 |
The present invention addresses the problem of providing a safe and efficacious antibody preparation so as to fundamentally overcome the difficulty that the national self-sufficiency of starting blood for producing anti-HBs human immunog...
|
|
WO/2022/023539A1 |
The present invention relates to a 68Ga-labeled gastrin analogue and its use in peptide receptor radionuclide diagnostic applications. In particular, the present invention relates to a 68Ga-labeled minigastrin analogue for use in a metho...
|
|
WO/2022/023439A1 |
This invention relates to radiolabelled compounds as described herein, precursor compounds and reference compounds, as well as pharmaceutical compositions comprising the radiolabelled compounds, which are for use in a diagnostic method p...
|
|
WO/2022/021528A1 |
The present invention belongs to the fields of radiopharmaceuticals and nuclear medicine, and relates to an ACE2 receptor targeting nuclide polypeptide probe and a preparation method therefor and the use thereof. The probe is DX600 or BF...
|
|
WO/2022/016231A1 |
The present invention is directed to methods of treating or preventing multiple myeloma in a patient in need thereof by administering 4-[211At]Astato-L-phenylalanine (4-[211At]APA) or a pharmaceutical derivative thereof to said patient.
|
|
WO/2022/018264A1 |
Provided is a ligand compound, comprising (a) a targeting group, (b) one or more chelating groups, optionally containing a chelated radioactive or non-radioactive cation, and (c) a group carrying an Si-OH functional moiety. The ligand co...
|
|
WO/2022/017375A1 |
A SPECT contrast agent for FAP-α-specific tumor diagnosis, said contrast agent being formed using a small molecule FAP-α inhibitor of a modified N-4-quinolinoyl-Gly-(2S)-cyanoPro scaffold as a precursor compound, using 99mTc as a radio...
|
|
WO/2022/013610A2 |
The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 1...
|
|
WO/2022/014555A1 |
This method for producing a 225Ac solution comprises steps (I)-(III). In step (I), a solution (1) containing 226Ra and 225Ac is passed through a solid-phase extractant (a) containing a compound represented by formula (A), and 225Ac is ...
|
|
WO/2022/014605A1 |
The present invention relates to a method for diagnosing pancreatic function, the method comprising the steps of: administering a diagnostic agent for pancreatic function to a subject, the agent containing a compound represented by gener...
|
|
WO/2022/008877A1 |
The invention relates to a composite material comprising polyaryletherketone, reinforcement fibre, and contrast agent. The reinforcement fibre is present in an amount of 52 to 58 volume % based on the total volume of the composite material.
|
|
WO/2022/011184A1 |
Disclosed herein is method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone, where the chelator comprises a one, and only one, derivatized carboxylic acid group ...
|
|
WO/2022/008688A1 |
The present invention relates to a set of antibodies which bind to antigens on target cells and which target radionuclides to said cells, and to methods of using the same. The antibodies each comprising a Fab binding to the target antige...
|
|
WO/2022/009649A1 |
This electromagnetic energy ray radiator has the following positional relationship in a conical or polyhedral structure: a mineral is disposed at each vertex of a hexahedron formed by combined two trigonal pyramids, and a meteoric stone ...
|
|
WO/2022/005994A1 |
Provided herein are compositions comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and an anti-DOTA C825 antigen binding fragment. The engineered immune cells of the present technology are...
|
|
WO/2022/002834A1 |
There is provided a composition comprising: (i) a compound of Formula I: (I), or a pharmaceutically acceptable salt thereof, and (ii) a nuclide M, or a pharmaceutically acceptable salt of the compound of Formula I and/or the nuclide M, w...
|
|
WO/2022/005998A1 |
The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel compounds that may be complexed with a radioisotope. Also disclose...
|
|
WO/2022/002022A1 |
A compound as represented by formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer or a diastereomer thereof, or a deuterium element substituent thereof. By means of complexing with a radionuclide, the compound can...
|
|
WO/2021/262174A1 |
A delivery assembly includes a console including a vial containment region and a vial engagement mechanism extending from the console within the vial containment region. The engagement mechanism is configured to engage a vial assembly in...
|
|
WO/2021/259869A1 |
The present invention relates to cell radiolabelling agents. The invention provides a method of preparing oxine-containing cell radiolabelling agents, a kit for the preparation of oxine-containing cell radiolabelling agents and a formula...
|
|
WO/2021/257552A1 |
Antibodies specific for uPAR and uPA-uPAR complexes in the form of radioconjugates with alpha particle—emitting radionuclides are disclosed as is their use in treating severe respiratory diseases such as severe COVID-19.
|
|
WO/2021/255282A1 |
The invention relates to the field of imaging, diagnostic, internal vectorized radiotherapy and nuclear medicine. Inventors herein describe new products for use for labelling, detecting and/or imaging angiogenesis, vasculogenesis or a ti...
|
|
WO/2021/257806A1 |
The present invention relates to the use of halogen compounds, including iodide, to treat and prevent NTIS and for immunosuppression.
|
|
WO/2021/257550A1 |
The present disclosure provides materials and methods for cloning antibodies from single cells in pooled sequence libraries by selective PCR. The compositions and methods relate to isolating, cloning, and/or expressing one or more antibo...
|
|
WO/2021/257542A1 |
Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to CD46 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the ligh...
|
|
WO/2021/251756A1 |
According to the present invention, a conjugate of an N-acylhydrazone derivative of chemical formula 1 and a marker, or a stereoisomer or pharmaceutically acceptable salt thereof specifically acts on cancer cells and accumulates, and is ...
|
|
WO/2021/250240A1 |
The invention relates to a diaza-18-crown-6 derivative having formula (I): wherein: B is a moiety for a covalent bonding reaction; the two A are identical to each other and are a group of formula (II): where: n = 0 to 4; X1, X2, X3, X4 a...
|
|
WO/2021/252664A1 |
Compounds of Formula (I) and Formula (II), which are capable of binding to granzyme B. Also provided herein are pharmaceutical compositions comprising such for use in, for example, imaging Granzyme B and/or treating immunoregulatory abno...
|
|
WO/2021/252448A1 |
The present technology is directed to compounds useful in the imaging of peripheral neurons.
|
|
WO/2021/252775A1 |
Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, especially huntingtin protein aggregation, compositions thereof, and methods of their use.
|
|
WO/2021/245263A1 |
The present invention provides novel PSMA targeting urea-based ligands that binds to prostate‐specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA ta...
|
|
WO/2021/243415A1 |
Provided herein is dendrimer-targeting agent conjugate comprising: (a) a dendrimer comprising i) a core unit (C); and ii) building units (BU), wherein the dendrimer has from two to six generations of building units; and wherein the core ...
|
|
WO/2021/245651A1 |
A method for predicting transplant-free survival of a patient suffering from acute liver failure (ALF) or acute liver injury (ALI), the method including: performing a 13C-methacetin breath test which includes administering 13C labelled m...
|
|
WO/2021/238529A1 |
Disclosed is a technetium [99mTc] carbon microsphere injection. The injection comprises carbon microspheres and radionuclide technetium [99mTc] adsorbed in the carbon microspheres. Every 1 ml of the injection contains 0.5-200 mg of carbo...
|
|
WO/2021/238842A1 |
The present invention relates to the technical field of clinical nuclear medicine, and relates to an HER2 affibody, a diagnostic or therapeutic nuclide-labeled substance, and a preparation method for the nuclide-labeled substance and an ...
|
|
WO/2021/234181A1 |
The present invention relates to a compound, a pharmaceutical composition comprising or consisting of said compound, a kit comprising or consisting of said compound or pharmaceutical composition and use of the compound or pharmaceutical ...
|
|
WO/2021/236080A1 |
The present invention relates to methods and compositions for the treatment of BAF-related disorders such as acute myeloid leukemia. The present invention features methods to treat AML, e.g., in a subject in need thereof. In one aspect, ...
|
